Abbott Laboratories' (ABT) "Buy" Rating Reiterated at TD Cowen

Key Points

• TD Cowen reiterated its “Buy” rating on Abbott Laboratories and set a $135 price target, implying approximately 26.4% upside from the reported share price of $106.82.
• Analyst sentiment remains positive, with Abbott receiving a consensus “Moderate Buy” rating and an average price target of $119.50 from MarketBeat-tracked analysts.
• Abbott’s latest quarterly results exceeded expectations: EPS was $1.31 versus a $1.28 consensus estimate, while revenue rose 13% year over year to $12.59 billion.

Abbott Laboratories (NYSE:ABT - Get Free Report)'s stock had its "buy" rating reiterated by TD Cowen in a research note issued on Tuesday, Benzinga reports. They currently have a $135.00 target price on the healthcare product maker's stock. TD Cowen's price objective indicates a potential upside of 26.38% from the company's current price.

ABT has been the subject of a number of other reports. Citigroup lifted their price objective on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a "buy" rating in a research note on Friday, July 17th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $130.00 price objective on shares of Abbott Laboratories in a research note on Friday, July 17th. Wells Fargo & Company lifted their price objective on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an "overweight" rating in a research note on Friday, July 17th. Weiss Ratings upgraded Abbott Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Thursday, August 6th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and an average price target of $119.50.

Abbott Laboratories Price Performance

Shares of NYSE:ABT traded down $1.51 during mid-day trading on Tuesday, reaching $106.82. The stock had a trading volume of 1,593,138 shares, compared to its average volume of 11,562,806. The business's 50 day moving average price is $104.74 and its 200 day moving average price is $100.00. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The company has a market cap of $184.83 billion, a P/E ratio of 34.64, a price-to-earnings-growth ratio of 2.01 and a beta of 0.59. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter in the previous year, the company posted $1.26 EPS. The company's revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Institutional Trading of Abbott Laboratories

A number of large investors have recently modified their holdings of ABT. Nia Impact Advisors LLC lifted its holdings in shares of Abbott Laboratories by 2.2% in the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker's stock worth $504,000 after buying an additional 79 shares during the period. Riggs Asset Managment Co. Inc. raised its holdings in shares of Abbott Laboratories by 9.3% in the second quarter. Riggs Asset Managment Co. Inc. now owns 1,031 shares of the healthcare product maker's stock valued at $140,000 after acquiring an additional 88 shares in the last quarter. Eley Financial Management Inc lifted its stake in Abbott Laboratories by 0.9% in the fourth quarter. Eley Financial Management Inc now owns 10,817 shares of the healthcare product maker's stock worth $1,355,000 after acquiring an additional 92 shares during the period. Copley Financial Group Inc. lifted its stake in Abbott Laboratories by 2.1% in the fourth quarter. Copley Financial Group Inc. now owns 4,435 shares of the healthcare product maker's stock worth $556,000 after acquiring an additional 93 shares during the period. Finally, Kelleher Financial Advisors grew its holdings in Abbott Laboratories by 2.9% during the 3rd quarter. Kelleher Financial Advisors now owns 3,301 shares of the healthcare product maker's stock worth $442,000 after acquiring an additional 93 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company's stock.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.